<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-29899" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Technetium-99m</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kane</surname>
            <given-names>Steven M.</given-names>
          </name>
          <aff>Wellstar Atlanta Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Padda</surname>
            <given-names>Inderbir S.</given-names>
          </name>
          <aff>Richmond University Medical Center/Mount Sinai</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Davis</surname>
            <given-names>Donald D.</given-names>
          </name>
          <aff>Wellstar Atlanta Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Steven Kane declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Inderbir Padda declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Donald Davis declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-29899.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Technetium-99m (99mTc) is an FDA-approved radionuclide agent for diagnostic imaging across various human organs, encompassing critical areas such as the brain, lungs, heart, and more. Following systemic administration,&#x000a0;99mTc is localized to its target tissue or organ. The duration and amount of radioactivity in the target tissue or organ provide insight into tissue function and potential disease status. A patient-centered approach is central to effective utilization, emphasizing collaborative efforts among healthcare professionals from diverse disciplines, including nuclear medicine specialists, radiologists, nurses, technologists, and clinicians. Coordination with the primary team is vital, particularly in scenarios like myocardial perfusion testing in patients with coronary artery disease, where continuous cardiac monitoring and access to emergency care are imperative for patient safety.</p>
        <p>This activity reviews the interprofessional collaboration to ensure proper preparation, administration, and interpretation of imaging studies, with nursing staff facilitating patient readiness and education regarding potential risks and benefits. This approach optimizes patient outcomes and upholds standards of safety in nuclear medicine imaging studies with 99mTc.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate clinical scenarios based on patient history and symptoms for technetium-99m (Tc-99m) imaging.</p></list-item><list-item><p>Differentiate between the various radiopharmaceuticals available and select the most suitable technetium-99m tracer for specific diagnostic purposes.</p></list-item><list-item><p>Screen patients based on the contraindications and potential adverse effects of technetium-99m.</p></list-item><list-item><p>Collaborate with the interprofessional team when ordering and interpreting the results of scans using technetium-99m to obtain diagnostic information while maintaining patient safety.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29899&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29899">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-29899.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Technetium-99m (99mTc) is a radionuclide isotope used primarily for diagnostic purposes in nuclear imaging.<xref ref-type="bibr" rid="article-29899.r1">[1]</xref> Technetium-99m&#x000a0;was isolated in 1938 from&#x000a0;molybdenum-99 (Mo-99) decay. In&#x000a0;1960 Richards&#x000a0;was the first to suggest using technetium as a medical tracer.<xref ref-type="bibr" rid="article-29899.r2">[2]</xref>&#x000a0;Now&#x000a0;99mTc is the&#x000a0;most common radioactive isotope tracer used for single-photon emission computerized tomography (SPECT) imaging of the brain, bones, lungs, kidneys, thyroid, heart, gall bladder, liver, spleen, bone marrow, salivary and lachrymal glands, blood pool, and sentinel nodes.<xref ref-type="bibr" rid="article-29899.r3">[3]</xref><xref ref-type="bibr" rid="article-29899.r4">[4]</xref></p>
        <p>Following systemic administration, the radioactive isotope is localized to its target tissue or organ based on the type of 99mTc administered. The duration and amount of radioactivity accumulated in the targeted tissue or organ can provide insight into tissue function and potential disease status.&#x000a0;99mTc is a more desirable radionuclide than other nuclear agents due to its six-hour half-life, which is enough time to permit imaging at a later period.<xref ref-type="bibr" rid="article-29899.r4">[4]</xref>&#x000a0;This can be more advantageous than positron emission tomography (PET), more short-lived isotopes.&#x000a0;</p>
        <p>99mTc can also provide greater insight than other diagnostic imaging studies as it can detect metabolic and functional irregularities at the nanomolar or subnanomolar level.&#x000a0;Furthermore,&#x000a0;the region of perfusion in an organ or tissue is evaluated by the radiotracer uptake, determining reversible or irreversible ischemia.<xref ref-type="bibr" rid="article-29899.r5">[5]</xref>&#x000a0;</p>
        <p>
<bold>FDA Approved&#x000a0;Technetium-99m Use</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Technetium-99m sodium pertechnetate - This variant is used for diagnostic imaging of the thyroid, salivary gland, urinary bladder, vesicoureteral reflux, and nasolacrimal drainage imaging. Its use in the gastrointestinal tract is primarily for diagnosing Meckel's diverticulum (Meckel&#x000a0;scintigraphy&#x000a0;scan).&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Technetium-99m sulfur colloid - Imaging of liver, spleen, and bone marrow, and is used for upper-gastrointestinal imaging assessing for reflux or gastric aspiration; it can also be useful to localize lymph nodes draining a malignant melanoma or breast cancer.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Technetium-99m tetrofosmin - Cardiac perfusion imagining, assessing the function of the left ventricle, and determining coronary artery disease&#x000a0;isolating ischemia and infarction</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Technetium-99m sestamibi - Cardiac perfusion imaging, assessing function, and localizing ischemia and infarction - also used for breast imaging.<xref ref-type="bibr" rid="article-29899.r5">[5]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Technetium-99m tilmanocept - Used to localize lymph node drainage of primary tumors</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Technetium-99m bicisate - Cerebral perfusion imagining used to localize the area of stroke</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Technetium-99m exametazine - Used for imaging abdominal infections, inflammatory bowel disease, and brain perfusion</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Technetium-99m pentetate - Imaging bone, kidney, and assessing pulmonary&#x000a0;embolism</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Technetium-99m pyrophosphate -Imaging bone, gastrointestinal bleeding, and myocardial infarction</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Technetium-99m red blood cells - Localizing gastrointestinal bleeding</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Technetium-99m succimer - Used for renal imaging</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Technetium-99m methylene&#x000a0;biphosphonate - Used for imaging bone</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Technetium-99m macroaggregated albumin - Used to assess pulmonary perfusion</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Technetium-99m mebrofenin - Used for hepatobiliary imaging</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Technetium-99m medronate - Used for imaging bone</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Technetium-99m mertiatide - Used for renal imaging</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Technetium-99m oxidronate - Used for imaging bone</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29899.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Technetium-99m is a radioactive isotope that exerts its mechanism of action by gamma-ray emission in the target tissue or organ, which is then picked up and captured by a unique gamma camera for medical imaging.<xref ref-type="bibr" rid="article-29899.r6">[6]</xref><xref ref-type="bibr" rid="article-29899.r7">[7]</xref>&#x000a0;99mTc is combined with a specific ligand and forms complexes that can then bind to its target tissue or organ with high affinity.<xref ref-type="bibr" rid="article-29899.r1">[1]</xref>&#x000a0;When&#x000a0;distributed throughout the body and localized to its target, 99mTc emits photons that can be captured for imaging with a SPECT or PET scan.<xref ref-type="bibr" rid="article-29899.r5">[5]</xref><xref ref-type="bibr" rid="article-29899.r8">[8]</xref>&#x000a0;</p>
        <p>A PET scan&#x000a0;further detects the target tissue or organ's metabolic or biochemical function and can reveal both normal and abnormal metabolic activity.&#x000a0;SPECT imaging captures a three-dimensional image of the target area where the radioactive tracer is distributed. This enables the assessment and evaluation of the perfusion and function of specific tissues and organs, which can be more advantageous than anatomical diagnostic imaging techniques like computed tomography (CT) scans and magnetic resonance imaging (MRI), which may only provide insight into structural information.<xref ref-type="bibr" rid="article-29899.r9">[9]</xref></p>
      </sec>
      <sec id="article-29899.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Technetium radiotracer&#x000a0;may be administered via injection intravenously (IV) or orally.<xref ref-type="bibr" rid="article-29899.r10">[10]</xref><xref ref-type="bibr" rid="article-29899.r7">[7]</xref>&#x000a0;After the specific radioactive isotope complex is administered, it accumulates&#x000a0;in the target organ or tissue. Following localization to the target tissue within the body, gamma rays are emitted by the Tc-99m, which are then captured for diagnostic imaging.<xref ref-type="bibr" rid="article-29899.r1">[1]</xref>&#x000a0;</p>
        <p>
<bold>Technetium-99m Sodium Pertechnetate&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Brain&#x000a0;scintigraphy (adult):&#x000a0;370&#x000a0;to 740 MBq (10&#x000a0;to 20 mCi)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Thyroid&#x000a0;scintigraphy&#x000a0;(adult):&#x000a0;37&#x000a0;to 370 MBq (1&#x000a0;to 10 mCi)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Salivary gland&#x000a0;scintigraphy&#x000a0;(adult):&#x000a0;37 to 185 MBq (1 to 5 mCi)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Blood pooling&#x000a0;scintigraphy&#x000a0;(adult):&#x000a0;370 to 1110 MBq (10 to 30 mCi)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Vesic-ureteral&#x000a0;scintigraphy&#x000a0;(adult):&#x000a0;18.5 to 37 MBq (0.5 to 1 mCi)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Nasolacrimal drainage&#x000a0;scintigraphy&#x000a0;(adult):&#x000a0;3.70 MBq (0.1 mCi)&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Brain&#x000a0;scintigraphy (children):&#x000a0;5.2 to 10.4 MBq (140 to 280 &#x000b5;Ci/kg)&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Thyroid&#x000a0;scintigraphy&#x000a0;(children):&#x000a0;2.2 to 3.0 MBq (60 to 80 &#x000b5;Ci/kg)&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Blood pooling&#x000a0;scintigraphy&#x000a0;(children):&#x000a0;5.2 to 10.4 MBq (140 to 280 &#x000b5;Ci/kg)&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Vesic-ureteral&#x000a0;scintigraphy&#x000a0;(children):&#x000a0;18.5 to 37 MBq (0.5 to 1.0 mCi)&#x000a0;<xref ref-type="bibr" rid="article-29899.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Technetium 99m-methylene Diphosphonate&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Skeletal scintigraphy(adult): 740 to 1110 MBq (20 to 30 mCi)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Skeletal scintigraphy(children): 9 to 11 MBq/kg (0.2 to 0.3 mCi/kg)</p>
          </list-item>
        </list>
        <p>
<bold>Technetium Tc99m Exametazime</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Cerebral flow scintigraphy: 370 to 740 MBq (10 to 20 mCi)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Leukocyte labeled scintigraphy: 259 to 925 MBq&#x000a0;(7 to 25 mCi)&#x000a0;<xref ref-type="bibr" rid="article-29899.r10">[10]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Technetium Tc 99m Sestamibi&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Myocardial perfusion scintigraphy 555 to 1110 MBq (15 to 30 mCi)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Parathyroid surgery preparation: 740 to 925&#x000a0;MBq&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Breast scintigraphy&#x000a0;740 to 1110&#x000a0;MBq&#x000a0;(20 to 30 mCi)&#x000a0;<xref ref-type="bibr" rid="article-29899.r7">[7]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Technetium-99m Tilmanocept&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Lymph node biopsy/scintigraphy: 18.5 MBq (0.5 mCi)&#x000a0;<xref ref-type="bibr" rid="article-29899.r12">[12]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Technetium-99m Macroaggregated Albumin&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Lung scintigraphy: 37 to 148 MBq&#x000a0;(1 to 4 mCi)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Portovenous shunt:&#x000a0;37 to 111 MBq&#x000a0;(1 to 3 mCi)&#x000a0;<xref ref-type="bibr" rid="article-29899.r13">[13]</xref></p>
          </list-item>
        </list>
        <p>Dosages may be modified depending on the patient and indications of imaging. Patients who receive the agent orally must fast for at least 6 hours before administration.</p>
      </sec>
      <sec id="article-29899.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Technetium-99m is a widely used radioactive isotope in nuclear medicine, and adverse effects may occur following systemic administration. Effects may occur secondary to the 99mTc or can be to the specific radiopharmaceutical it is tagged to. The most commonly reported effects include hypersensitivity-like reactions such as rash, angioedema, fever, and anaphylaxis.<xref ref-type="bibr" rid="article-29899.r14">[14]</xref>&#x000a0;In cases&#x000a0;of a severe hypersensitivity-type reaction, corticosteroids, antihistamines, and epinephrine should be available for prompt administration.<xref ref-type="bibr" rid="article-29899.r7">[7]</xref>&#x000a0;Patients may also experience a transient increase in blood pressure, seizures, arrhythmias, and syncope.&#x000a0;When used for abdominal imaging, gastrointestinal symptoms such as abdominal pain and discomfort, nausea, vomiting, and diarrhea may also occur. Other adverse effects include transient arthritis if the joint is affected.&#x000a0;</p>
        <p>Adverse effects associated with 99mTc sestamibi include pain&#x000a0;or discomfort&#x000a0;of the breasts (mastalgia), distortion in taste sensations (dysgeusia), angina pectoris, chest pain or discomfort, and ST-segment electrocardiogram (ECG) changes.&#x000a0;Proton pump inhibitors (PPI) should also be held for 72 hours before diagnostic myocardial perfusion imaging with 99mTc sestamibi as&#x000a0;these drugs may lower the effect of the radioactive agent.&#x000a0;Mortality has also been reported in patients with severe pulmonary hypertension and 99mTc macroaggregated albumin use.<xref ref-type="bibr" rid="article-29899.r15">[15]</xref></p>
      </sec>
      <sec id="article-29899.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Technetium-99m is&#x000a0;labeled as pregnancy category C&#x000a0;due to insufficient studies on pregnant women. Breastfeeding is a contraindication to its use as&#x000a0;10% of the agent may be excreted in breast milk during lactation.<xref ref-type="bibr" rid="article-29899.r16">[16]</xref> Patients are advised to pump and discard breast milk&#x000a0;for up to 60 hours post-99mTc administration, and the recommendation is to formula feed the infant.<xref ref-type="bibr" rid="article-29899.r17">[17]</xref>&#x000a0;Furthermore, a previously documented hypersensitivity reaction to 99mTc&#x000a0;is a contraindication. Patients with severe pulmonary hypertension are contraindicated&#x000a0;to receive 99mTc macroaggregated albumin for lung imaging. Hypersensitivity albumin is also a contradiction to 99mTc macroaggregated albumin.</p>
      </sec>
      <sec id="article-29899.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Technetium-99m can be administered to both adults and children. Extra precautions&#x000a0;are necessary with children as the pediatric population&#x000a0;is at higher risk for radiation exposure than adults. In contrast, new mothers exposed&#x000a0;to 99mTc agents at their workplace do not require special precautions other than general&#x000a0;protective care&#x000a0;from radiation exposure.<xref ref-type="bibr" rid="article-29899.r17">[17]</xref>&#x000a0;Patients with suspected or known CAD who undergo myocardial perfusion testing using 99mTc sestamibi require cardiac event monitoring during diagnosis.<xref ref-type="bibr" rid="article-29899.r18">[18]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-29899.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Technetium-99m has a&#x000a0;photopeak of gamma-ray emission of 140.5 keV, meaning it has a very minimal risk of toxicity.<xref ref-type="bibr" rid="article-29899.r4">[4]</xref> The short six-hour half-life and rapid excretion from the body limit toxic effects and give enough time to perform its diagnostic imaging, all while limiting radiation exposure to the patient.<xref ref-type="bibr" rid="article-29899.r3">[3]</xref><xref ref-type="bibr" rid="article-29899.r4">[4]</xref>&#x000a0;The kidneys excrete a portion of 99mTc, so patients with impaired&#x000a0;renal function require dosing modifications&#x000a0;to minimize their additional radiation exposure.</p>
      </sec>
      <sec id="article-29899.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Technetium-99m is a radionuclide nuclear agent that is FDA-approved for diagnostic imaging of various organs of the human body, which include the brain, bone, lungs, kidneys, thyroid, heart, gall bladder, liver, spleen, bone marrow, salivary and lachrymal glands, blood pool, and sentinel nodes. Patient-centered care is an essential element of medical practice that involves a collaborative approach among healthcare professionals to improve outcomes and patient safety and enhance team performance. The use of 99mTc should be&#x000a0;utilized by an interprofessional team, which includes a nuclear medicine specialist, radiologist, nurse, technologist, and&#x000a0;clinician specializing in their respective field.&#x000a0;</p>
        <p>Professionals trained to administer 99mTc are referred to as nuclear medicine technologists. They should be fully trained and specialized in radiation safety, dosimetry, and imaging techniques and able to perform their roles competently. They should also be familiar with the preparation of the kit before administration and any acute life-threatening adverse effects, such as hypersensitivity reactions that may occur during administration. If&#x000a0;hypersensitivity or anaphylaxis occurs, the healthcare team should be fully prepared and equipped with&#x000a0;prompt interventions such as corticosteroids and antihistamines.&#x000a0;Patients with a history of CAD undergoing myocardial perfusion testing with 99mTc sestamibi must have continuous cardiac monitoring during the diagnostic evaluation. The procedure should&#x000a0;be conducted where appropriate treatment is available during a cardiac emergency.&#x000a0;</p>
        <p>Nuclear medicine technologists should also coordinate with the primary team and specialist who interpret the imaging studies to ensure timely diagnostic intervention is executed to prevent further delay of care.&#x000a0;Clinicians interpreting the radionuclide scan should have expertise in nuclear medicine imaging and the interpretation of 99mTc studies. Interprofessional communication and coordination are crucial in optimizing patient-centered care using 99mTc. The technologist should coordinate with the primary team to provide accurate information to the&#x000a0;clinician regarding the preparation of the kit and administration of the radiopharmaceutical. The primary team should further thoroughly inform patients about preparatory instructions before imaging, the benefits and risks of the imaging study, and the expected outcomes.</p>
        <p>The interprofessional team should confirm the kit is appropriately labeled with the radiopharmaceutical's expiration date and that the appropriate radiation safety measures are in place to prevent any harm to the patient.&#x000a0;Patients should be counseled and provided information on the risks of administering 99mTc during pregnancy, as it is a pregnancy category C contraindication. Patients should receive clear explanations of radiation toxicity and avoidance of breastfeeding during pregnancy.&#x000a0;</p>
        <p>Effective communication and care coordination is essential to optimize&#x000a0;diagnostic imaging using&#x000a0;99mTc. Nursing staff should communicate routinely with the nuclear medicine technologist and primary team to ensure that the patient scheduled for the nuclear imaging study is well-prepared.&#x000a0;The healthcare team should also counsel patients on the adverse effects of 99mTc, the early and late complications that may arise, and their severity.&#x000a0;Coordinated activity&#x000a0;within an interprofessional team can minimize adverse effects and optimize the results of the diagnostic modalities&#x000a0;when using&#x000a0;99mTc in nuclear medicine imaging studies. Collaborative efforts from physicians, nuclear technologists, nurses, nuclear pharmacists, and other health professionals involved in the administration of 99mTc should demonstrate specific skills, strategies, ethics, and interprofessional communication to provide optimal care to the patient. Care coordination and ethical practice are crucial in enhancing diagnostic quality, outcomes, patient safety, and team performance.&#x000a0;</p>
      </sec>
      <sec id="article-29899.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29899&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29899">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/29899/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=29899">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-29899.s11">
        <title>References</title>
        <ref id="article-29899.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Papagiannopoulou</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Technetium-99m radiochemistry for pharmaceutical applications.</article-title>
            <source>J Labelled Comp Radiopharm</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>60</volume>
            <issue>11</issue>
            <fpage>502</fpage>
            <page-range>502-520</page-range>
            <pub-id pub-id-type="pmid">28618064</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29899.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richards</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tucker</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Srivastava</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Technetium-99m: an historical perspective.</article-title>
            <source>Int J Appl Radiat Isot</source>
            <year>1982</year>
            <month>Oct</month>
            <volume>33</volume>
            <issue>10</issue>
            <fpage>793</fpage>
            <page-range>793-9</page-range>
            <pub-id pub-id-type="pmid">6759417</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29899.r3">
          <label>3</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Adams</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Banks</surname>
                <given-names>KP</given-names>
              </name>
            </person-group>
            <chapter-title>Bone Scan</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>14</day>
            <pub-id pub-id-type="pmid">30285381</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29899.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Green</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Technetium-99m production issues in the United Kingdom.</article-title>
            <source>J Med Phys</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>37</volume>
            <issue>2</issue>
            <fpage>66</fpage>
            <page-range>66-71</page-range>
            <pub-id pub-id-type="pmid">22557795</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29899.r5">
          <label>5</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Patel</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Alzahrani</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <chapter-title>Myocardial Perfusion Scan</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>14</day>
            <pub-id pub-id-type="pmid">30969594</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29899.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uzunov</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Melendez-Alafort</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bello</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cicoria</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zagni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>De Nardo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Selva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rossi-Alvarez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pupillo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Di Domenico</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Uccelli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Boschi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Groppi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Salvini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Taibi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Duatti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pasquali</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Loriggiola</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marengo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Strada</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Manenti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rosato</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Esposito</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Radioisotopic purity and imaging properties of cyclotron-produced <sup>99m</sup>Tc using direct <sup>100</sup>Mo(p,2n) reaction.</article-title>
            <source>Phys Med Biol</source>
            <year>2018</year>
            <month>Sep</month>
            <day>19</day>
            <volume>63</volume>
            <issue>18</issue>
            <fpage>185021</fpage>
            <pub-id pub-id-type="pmid">30229740</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29899.r7">
          <label>7</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Rizk</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Nagalli</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Technetium 99m Sestamibi</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">31985941</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29899.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>WW</given-names>
              </name>
              <collab>K-SPECT Group</collab>
            </person-group>
            <article-title>Clinical Applications of Technetium-99m Quantitative Single-Photon Emission Computed Tomography/Computed Tomography.</article-title>
            <source>Nucl Med Mol Imaging</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>53</volume>
            <issue>3</issue>
            <fpage>172</fpage>
            <page-range>172-181</page-range>
            <pub-id pub-id-type="pmid">31231437</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29899.r9">
          <label>9</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Yandrapalli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Puckett</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <chapter-title>SPECT Imaging</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>10</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">33232084</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29899.r10">
          <label>10</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Dinh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>McWhorter</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <chapter-title>Triple Phase Bone Scan</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">30571011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29899.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Altmann</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Henrich</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schaub</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thiel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Moritz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>[99m-Technetium-pertechnetate- and 99m-Technetium-sestamibi-scintigraphy for visualization of hypofunctioning thyroid tissue and staging in a dog with thyroid carcinoma].</article-title>
            <source>Tierarztl Prax Ausg K Kleintiere Heimtiere</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>50</volume>
            <issue>6</issue>
            <fpage>446</fpage>
            <page-range>446-456</page-range>
            <pub-id pub-id-type="pmid">36516844</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29899.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mwagiru</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shivashankar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Farlow</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cambden</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Abdul-Razak</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Tilmanocept as a novel tracer for lymphatic mapping and sentinel lymph node biopsy in melanoma and oral cancer.</article-title>
            <source>ANZ J Surg</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>92</volume>
            <issue>10</issue>
            <fpage>2607</fpage>
            <page-range>2607-2612</page-range>
            <pub-id pub-id-type="pmid">35848587</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29899.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Namous</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kushner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dadparvar</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>99m Tc-Macroaggregated Albumin Liver Lung Shunt Study With Uptake Indicative of Patent Falciform Artery.</article-title>
            <source>Clin Nucl Med</source>
            <year>2023</year>
            <month>Jun</month>
            <day>01</day>
            <volume>48</volume>
            <issue>6</issue>
            <fpage>510</fpage>
            <page-range>510-511</page-range>
            <pub-id pub-id-type="pmid">36179332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29899.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramos-Gabatin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Orzel</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Maloney</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Murnane</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Borchert</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Severe systemic reaction to diphosphonate bone imaging agents: skin testing to predict allergic response and a safe alternative agent.</article-title>
            <source>J Nucl Med</source>
            <year>1986</year>
            <month>Sep</month>
            <volume>27</volume>
            <issue>9</issue>
            <fpage>1432</fpage>
            <page-range>1432-5</page-range>
            <pub-id pub-id-type="pmid">3018201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29899.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Norouzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>AsadZade</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Salimi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Khoshbakht</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pirayesh</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Effect of proton pump inhibitors and H2 antagonists on gastric wall uptake in myocardial perfusion scan with 99mTc-sestamibi.</article-title>
            <source>J Nucl Cardiol</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>1552</fpage>
            <page-range>1552-1561</page-range>
            <pub-id pub-id-type="pmid">33527332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29899.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <chapter-title>Sodium Pertechnetate Tc 99m</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>10</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29899.r17">
          <label>17</label>
          <element-citation publication-type="book">
            <chapter-title>Technetium Tc 99m Exametazime</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>10</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000634</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29899.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alenezi</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Majrashi</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Sharif</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Alyami</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Ageeli</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Salawi</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Refaee</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Alanazi</surname>
                <given-names>SF</given-names>
              </name>
            </person-group>
            <article-title>A systemic review of rubidium-82 PET contrasted with 99mTc-MIBI SPECT for imaging coronary artery disease.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2023</year>
            <month>Mar</month>
            <day>10</day>
            <volume>102</volume>
            <issue>10</issue>
            <fpage>e33068</fpage>
            <pub-id pub-id-type="pmid">36897709</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
